Clinical Trials in the USA / NCT07933783
Enrolling by invitation
Phase 2
An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT07933783 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Plaque Psoriasis
Investigational drug(s) / intervention(s)
ORKA-002: ORKA-002 administered by subcutaneous (SC) injection
Study summary
An open-label study with maintenance dosing to evaluate the long-term safety and efficacy of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Eligibility
Inclusion Criteria:
1. Signed informed consent by participants from previous trial choosing to transition into the Open-label study.
2. Participants who have successfully completed the preceding trial.
3. For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
4. For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception.
Exclusion Criteria:
1. Participants who experienced any adverse events with ORKA-002 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-002.
2. Participants whom the Investigator feels would not benefit from treatment with open-label ORKA-002.
3. Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
4. Participants who, while in ORKA-002-212, developed a new intercurrent illness or diagnosis/suspected diagnosis which, in the opinion of the Investigator, indicates that continued treatment and/or participation in the study is not in the participant's best interest.
5. Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
6. Participant is pregnant or breastfeeding.
Primary outcome measure(s)
- Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs of Special Interest (TEAESIs) — Day 1 through Week 144
Incidence of treatment adverse events, serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms.
Trial sites (8)
| Facility | City | Region | Status |
|---|---|---|---|
| Oruka Therapeutics Investigative Site | Fountain Valley | California | |
| Oruka Therapeutics Investigative Site | Milford | Massachusetts | |
| Oruka Therapeutics Investigative Site | New Brighton | Minnesota | |
| Oruka Therapeutics Investigative Site | Wilmington | North Carolina | |
| Oruka Therapeutics Investigative Site | Warrenton | Oregon | |
| Oruka Therapeutics Investigative Site | Barrie | Ontario | |
| Oruka Therapeutics Investigative Site | North Bay | Ontario | |
| Oruka Therapeutics Investigative Site | Toronto | Ontario |
More Oruka Therapeutics, Inc. trials in the USA
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Active, not recruiting
Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Active, not recruiting
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Active, not recruiting
Other trials for the same condition
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Active, not recruiting
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07933783 on ClinicalTrials.gov ↗ ← All trials in the USA